ReviewStem cell research & therapy2013
Clinical translation of human neural stem cells.
Review in Stem cell research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Are Cell-Based Therapies Safe and Effective in the Treatment of Neurodegenerative Diseases? A Systematic Review with Meta-Analysis.Biomolecules · 2022Pooled it
- Neural stem cell treatment for perinatal brain injury: A systematic review and meta-analysis of preclinical studies.Stem cells translational medicine · 2021Pooled it
- Stretch-activated ion channel Piezo1 directs lineage choice in human neural stem cells.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Translating potential into practice: the evolving landscape of neural stem cell therapeutics in clinical applications.Annals of medicine and surgery (2012) · 2026Review
- An improved formulation of human neural stem cells for the treatment of geographic atrophy.PloS one · 2026Article
- Updates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024).Pediatric research · 2025Article
- Therapeutic application of extracellular vesicles in human diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Cell therapy for neurological disorders.Nature medicine · 2024Review
- Local delivery of EGFRBioactive materials · 2024Article
- Advancing cell therapy for neurodegenerative diseases.Cell stem cell · 2023Review
- Article
- Acceptability of neural stem cell therapy for cerebral palsy: survey of the Australian cerebral palsy community.Stem cell research & therapy · 2023Article
- Subcutaneous priming of protein-functionalized chitosan scaffolds improves function following spinal cord injury.Materials science & engineering. C, Materials for biological applications · 2020Article
- Melatonin Protects Neural Stem Cells Against Tri-Ortho-Cresyl Phosphate-Induced Autophagy.Frontiers in molecular neuroscience · 2020Article
- Regenerative medicine: could Parkinson's be the first neurodegenerative disease to be cured?Future science OA · 2019Review
- Examining the fundamental biology of a novel population of directly reprogrammed human neural precursor cells.Stem cell research & therapy · 2019Article
- Article
- Cell Therapy for Retinal Dystrophies: From Cell Suspension Formulation to Complex Retinal Tissue Bioengineering.Stem cells international · 2019Review
- Bringing Neural Cell Therapies to the Clinic: Past and Future Strategies.Molecular therapy. Methods & clinical development · 2017Review
- Generation of Human Induced Pluripotent Stem Cell-Derived Bona Fide Neural Stem Cells for Ex Vivo Gene Therapy of Metachromatic Leukodystrophy.Stem cells translational medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human neural stem cell transplants have potential as therapeutic candidates to treat a vast number of disorders of the central nervous system (CNS). StemCells, Inc. has purified human neural stem cells and developed culture conditions for expansion and banking that preserve their unique biological properties. The biological activity of these human central nervous system stem cells (HuCNS-SC®) has been analyzed extensively in vitro and in vivo. When formulated for transplantation, the expanded and cryopreserved banked cells maintain their stem cell phenotype, self-renew and generate mature oligodendrocytes, neurons and astrocytes, cells normally found in the CNS. In this overview, the rationale and supporting data for pursuing neuroprotective strategies and clinical translation in the three components of the CNS (brain, spinal cord and eye) are described. A phase I trial for a rare myelin disorder and phase I/II trial for spinal cord injury are providing intriguing data relevant to the biological properties of neural stem cells, and the early clinical outcomes compel further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.